{"ticker": {"uuid": "34c95a65-3897-434d-a9d2-a51fdf5f7f46", "symbol": "HBIO", "name": "Harvard Bioscience Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Medical Instruments & Supplies"}, "articles": [{"title": "Harvard Bioscience focuses on life science instruments as investors weigh long-term demand", "summary": "Harvard Bioscience (HBIO) is a life science tools company that specializes in preclinical research instruments and laboratory systems. The company's business model relies on selling capital equipment, consumables, and services to pharmaceutical and biotechnology companies, contra", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/harvard-bioscience-focuses-on-life-science-instruments-as-investors-weigh/69732093", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-09T13:11:50", "published_display": "09 Jul 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience focuses on lab equipment growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPVTBhU2hyMS1IZUtsVW5vV09PSWVGdFd0OW5adnVtM2QzMDRUd0ZFUG5DemRGbjdGbDA2Qkw4TnpjdGFwc2JfZEpjMTVRa0cyVjVMRllMMWNHYTA4ZkpNZWRBTnBtUElaZlVCQWJEYnFmbW12ZVF5T3JwcXlBZC13TXR1aFVXc3ItMDVINUVMZkNLSmlkaFpuaEtwXzR3bGs0eGl0RHpodm4wcHBDMUE?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-07T20:22:01+00:00", "published_display": "07 Jul 2026 20:22", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience (HBIO) Hovers Near Support Amid Low-Volume Trading - Bollinger Walk", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQT1ZtRTRxLW10V1pnMVAxRC1EaDIzOTFKMUxOelZoU2R0NjlZMnAyX1c5ZHNER2tuWnBCWkdfZ2tLbWlrbkhHaTE4eG51OXBOT2hwNk1mRWtUa1hWM1IxU1dCMkFQa2JYbTVzWGRDTWZhNjBrT25VV2dNUkZhdHE2VEJYWThGcWNDbFQ1TTlkaVJ4WDFXNlFvX25GTGtNbGlTMVR6WVBCU3dWZkJmRWww?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience | SD: Specialized disclosure report", "summary": "This article is a specialized disclosure report from Harvard Bioscience. The content of the report is provided in the document.", "url": "https://www.moomoo.com/news/notice/307395749/harvard-bioscience-sd-specialized-disclosure-report", "source_name": "Moomoo", "published_at": "2026-07-04T15:10:59", "published_display": "04 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience, Inc. Actuals & Estimates (NASDAQ:HBIO)", "summary": "This article provides an overview of Harvard Bioscience, Inc. (HBIO) stock performance, analyst estimates, and financial data. It covers current stock price, market capitalization, earnings, revenue, and future forecasts. The company's next earnings report is expected on July 30,", "url": "https://www.tradingview.com/symbols/NASDAQ-HBIO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:40:10", "published_display": "26 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Harvard Bioscience, Inc. \u2013 NASDAQ:HBIO", "summary": "This article provides a brief snapshot of Harvard Bioscience, Inc. (NASDAQ: HBIO) financial data, specifically focusing on its forward price-to-sales ratio. It appears to be a stub or an outdated page from a financial data platform like TradingView, intended to display financial ", "url": "https://www.tradingview.com/symbols/NASDAQ-HBIO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T13:12:05", "published_display": "25 Jun 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HBIO Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Harvard Bioscience, Inc. (HBIO) stock, based on analyst opinions. It details current stock performance, historical highs and lows, volatility, market capitalization, and upcoming earnings reports, along with financial data lik", "url": "https://www.tradingview.com/symbols/NASDAQ-HBIO/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-23T17:41:15", "published_display": "23 Jun 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience Inc (HBIO) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Harvard Bioscience Inc (HBIO) has a current financial score of 7.02, indicating a weak financial status despite high operating efficiency, ranking 114 out of 203 in its industry. The company's recent quarterly revenue decreased by 4.68% year-over-year to $20.75M, while net profit", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hbio/financial-health", "source_name": "TradingKey", "published_at": "2026-06-23T08:13:38", "published_display": "23 Jun 2026 08:13", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience (HBIO) Slips Slightly, Holding Above Support at $5.71 - Quality Factor", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOWE96ZG1adjg0bHE5dm1zb2JpWjM1T2puRUJsU1pxMGF4bEJfMTExVS1Uc3JrQjd6NXlDVFNKRHBjRTBLODdaLVZXWThVYXVqeUZDQjRJTkNsek5hakdnUENuVWZWaFMxZXh3cmZPTW5EZnRhR3hGdW9rRy1Bb0tSZ2xsNmFzVEtFRlpOTU9Ba045Y3Nfempya1dXQXRHYk8zbV8xVmRmOXRyb3VsTXc?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience holds key trading range, shares between support and resistance", "summary": "Harvard Bioscience (HBIO) is currently trading within a defined range on Nasdaq, with technical analysis indicating support at $5.10 and resistance at $6.65. Despite a relatively solid momentum score, short-term signals are cautious, with more sell than buy indicators reported by", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/harvard-bioscience-holds-key-trading-range-shares-between-support-and/69606091", "source_name": "AD HOC NEWS", "published_at": "2026-06-22T20:10:18", "published_display": "22 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience Inc (HBIO) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Harvard Bioscience Inc (HBIO), noting its current valuation score is 9.02, ranking it 46 out of 203 in the Healthcare Equipment & Supplies industry. It highlights the company's P/E ratio of -2.77, while stating that relevant data for ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hbio/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T20:10:31", "published_display": "18 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience Inc (HBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Harvard Bioscience Inc (HBIO), detailing its current price momentum score, support and resistance levels, and indicator readings. It also outlines the stock's moving average status, with a current overall signal of \"Sell\" based on tec", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hbio/technical", "source_name": "TradingKey", "published_at": "2026-06-18T10:38:54", "published_display": "18 Jun 2026 10:38", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience Inc (HBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Harvard Bioscience Inc (HBIO), highlighting its current earnings forecast score and analyst ratings. It details the average price target, expected revenue for the next quarter, and historical as well as forecasted EPS. The report ind", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hbio/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T09:38:54", "published_display": "18 Jun 2026 09:38", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience Inc (HBIO) Institutional Confidence", "summary": "Harvard Bioscience Inc (HBIO) has an institutional shareholding score of 5.00, placing it 109th out of 204 in the Healthcare Equipment & Supplies industry. Institutional shareholding proportion increased by 13.62% quarter-over-quarter to 54.17%. James Simons is the largest instit", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hbio/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T09:38:54", "published_display": "18 Jun 2026 09:38", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Harvard Bioscience (HBIO) granted 16,556 restricted stock units", "summary": "Harvard Bioscience director Katherine A. Eade was granted 16,556 restricted stock units (RSUs) of common stock at no cost. These RSUs will vest either before the company's next annual meeting or one year from the grant date, whichever comes first. Following this transaction, Eade", "url": "https://www.stocktitan.net/sec-filings/HBIO/form-4-harvard-bioscience-inc-insider-trading-activity-7ad08f78d51f.html", "source_name": "Stock Titan", "published_at": "2026-06-12T16:08:44", "published_display": "12 Jun 2026 16:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience (HBIO) director awarded 16,556 restricted stock units", "summary": "Harvard Bioscience director William Snider was granted 16,556 restricted stock units (RSUs) as compensation, which will vest either before the next annual meeting or one year from the grant date. This award increases his total holdings to 48,556 common share equivalents, includin", "url": "https://www.stocktitan.net/sec-filings/HBIO/form-4-harvard-bioscience-inc-insider-trading-activity-ae3acf126e4c.html", "source_name": "Stock Titan", "published_at": "2026-06-11T16:40:05", "published_display": "11 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience (NASDAQ: HBIO) awards director 16,556 RSUs", "summary": "Harvard Bioscience (NASDAQ: HBIO) director Stephen J. Denelsky was granted 16,556 restricted stock units (RSUs) as reported in a Form 4 SEC filing. These RSUs will vest either immediately before the company's next annual meeting or one year from the grant date, serving as a time-", "url": "https://www.stocktitan.net/sec-filings/HBIO/form-4-harvard-bioscience-inc-insider-trading-activity-9a5a18d8c248.html", "source_name": "Stock Titan", "published_at": "2026-06-11T13:39:17", "published_display": "11 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Harvard Bioscience (HBIO) awarded 16,556 RSUs", "summary": "Harvard Bioscience director Seth Benjamin Benson was granted 16,556 restricted stock units (RSUs) of common stock at a price of $0.0000 per share. These RSUs will vest either immediately before the company\u2019s next annual meeting or one year from the grant date, whichever comes fir", "url": "https://www.stocktitan.net/sec-filings/HBIO/form-4-harvard-bioscience-inc-insider-trading-activity-be1b781c385b.html", "source_name": "Stock Titan", "published_at": "2026-06-11T13:39:17", "published_display": "11 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience | 8-K: Harvard Bioscience Announces First Quarter 2026 Financial Results", "summary": "This article is a placeholder indicating that Harvard Bioscience announced its First Quarter 2026 Financial Results via an 8-K filing. The content displayed is merely a document placeholder, suggesting the detailed results would be within the actual 8-K filing.", "url": "https://www.moomoo.com/news/notice/307279199/harvard-bioscience-8-k-harvard-bioscience-announces-first-quarter-2026", "source_name": "Moomoo", "published_at": "2026-06-03T03:10:21", "published_display": "03 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience (NASDAQ: HBIO) shareholders approve equity and ESPP share increases", "summary": "Harvard Bioscience, Inc. shareholders approved key proposals at their 2026 Annual Meeting, including an increase of 400,000 shares for their 2021 Incentive Plan and amendments to the Employee Stock Purchase Plan. Shareholders also re-elected two Class II directors, ratified Grant", "url": "https://www.stocktitan.net/sec-filings/HBIO/8-k-harvard-bioscience-inc-reports-material-event-4d7925889f27.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:09:46", "published_display": "02 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience (HBIO) price target increased by 200.00% to 6.12", "summary": "This article reports that the price target for Harvard Bioscience (HBIO) has been significantly increased by 200.00% to $6.12. No further details are provided in the snippet.", "url": "https://www.msn.com/en-us/money/topstocks/harvard-bioscience-hbio-price-target-increased-by-20000-to-612/ar-AA1ZAgZk", "source_name": "MSN", "published_at": "2026-06-01T01:39:44", "published_display": "01 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HBIO - Harvard Bioscience Inc Website Traffic and Mobile Apps Usage", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE5DZjRUNHZJMVBFTVlfOENRQkNKYko1bWRtSVozUmhDeUl0cFBfSUdZXzRuX1AxUmNBUldiSVpCeWVaOTZpNDJDOUEwMGJ4UQ?oc=5", "source_name": "Finviz", "published_at": "2026-05-27T17:43:19+00:00", "published_display": "27 May 2026 17:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HBIO PE Ratio & Valuation, Is HBIO Overvalued", "summary": "Harvard Bioscience Inc (HBIO) is currently considered to be in the \"Fair zone,\" with its forward PE ratio of 15.06 fairly comparable to its five-year average of 23.52. The fair price for HBIO is estimated to be between $2.40 and $14.02 based on a relative valuation method. While ", "url": "https://intellectia.ai/en/stock/HBIO/valuation", "source_name": "Intellectia AI", "published_at": "2026-05-25T00:40:21", "published_display": "25 May 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience stock (US4169061052): Q2 2025 mixed results still define the story", "summary": "Harvard Bioscience (HBIO) reported mixed results for Q2 2025, with revenue missing estimates but adjusted earnings matching expectations thanks to improved cash flow and cost control. The company, a small-cap medtech supplier, operates in the life sciences research sector, making", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/harvard-bioscience-stock-us4169061052-q2-2025-mixed-results-still/69390990", "source_name": "AD HOC NEWS", "published_at": "2026-05-21T12:10:11", "published_display": "21 May 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:HBIO) 2026-05-15", "summary": "Harvard Bioscience, Inc. (NASDAQ:HBIO) published its Q1 2026 earnings call presentation, reporting an EPS of -$0.33, missing estimates by $0.30, and revenue of $20.76M, a 4.68% year-over-year decrease, missing by $445.00K. The article highlights that the slide deck was released i", "url": "https://seekingalpha.com/article/4905504-harvard-bioscience-inc-2026-q1-results-earnings-call-presentation?source=feed_all_articles", "source_name": "Seeking Alpha", "published_at": "2026-05-16T00:09:11", "published_display": "16 May 2026 00:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience (HBIO) insider entity reports 293,676 shares, 6.5% stake", "summary": "Harvard Bioscience (HBIO) investor Adam M. Hutt, as Managing Member of Leviticus Partners, has filed a Schedule 13G/A, disclosing beneficial ownership of 293,676 shares of Common Stock, representing a 6.5% stake in the company. The filing indicates sole voting and dispositive pow", "url": "https://www.stocktitan.net/sec-filings/HBIO/schedule-13g-a-harvard-bioscience-inc-amended-passive-investment-disc-d8fcc6606613.html", "source_name": "Stock Titan", "published_at": "2026-05-14T16:39:10", "published_display": "14 May 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discontinued operations of Harvard Bioscience, Inc. \u2013 FWB:HBI0", "summary": "The article reports on the discontinued operations of Harvard Bioscience, Inc., traded on the Frankfurt Stock Exchange under the symbol HBI0. It appears to be a financial news brief, likely indicating a change in the company's operational status. The content is brief and serves a", "url": "https://www.tradingview.com/symbols/FWB-HBI0/financials-income-statement/discontinued-operations/", "source_name": "TradingView", "published_at": "2026-05-13T23:40:23", "published_display": "13 May 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience, Inc. (NASDAQ:HBIO) Q1 2026 Earnings Call Transcript", "summary": "Harvard Bioscience, Inc. (NASDAQ:HBIO) reported its Q1 2026 earnings, highlighting continued progress in transforming into a translational science market supplier. The company beat earnings expectations with an EPS of $-0.33, against an expected $-0.62, and saw revenue of $20.8 m", "url": "https://www.insidermonkey.com/blog/harvard-bioscience-inc-nasdaqhbio-q1-2026-earnings-call-transcript-1761091/", "source_name": "Insider Monkey", "published_at": "2026-05-13T12:08:50", "published_display": "13 May 2026 12:08", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience: Q1 Earnings Snapshot", "summary": "Harvard Bioscience Inc. (HBIO) reported a Q1 loss of $3.4 million, or 77 cents per share. Adjusted for certain costs, the loss was 33 cents per share. The medical instruments company also projected Q2 revenue to be between $20.5 million and $22.5 million.", "url": "https://www.ktvb.com/article/syndication/associatedpress/harvard-bioscience-q1-earnings-snapshot/616-7a6b632f-bd2c-4309-8b66-26b56347923e", "source_name": "KTVB", "published_at": "2026-05-13T05:09:11", "published_display": "13 May 2026 05:09", "sentiment": "negative", "sentiment_pct": 36, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience Announces First Quarter 2026 Financial Results", "summary": "Harvard Bioscience (Nasdaq: HBIO) reported its first-quarter 2026 financial results, with revenues of $20.8 million and a gross margin of 59%. The company is progressing with the consolidation of manufacturing operations and reaffirmed its full-year 2026 financial guidance, antic", "url": "https://www.sahmcapital.com/news/content/harvard-bioscience-announces-first-quarter-2026-financial-results-2026-05-12", "source_name": "Sahm", "published_at": "2026-05-13T04:39:10", "published_display": "13 May 2026 04:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience reaffirms 2026 outlook for 2%-4% revenue growth as Project Viking targets $4M annual savings", "summary": "Harvard Bioscience (HBIO) has reaffirmed its 2026 outlook, projecting 2-4% organic revenue growth and an adjusted EBITDA margin of 20-22%. The company's 'Project Viking' initiative is expected to achieve approximately $4 million in annual run-rate savings, contributing to its goa", "url": "https://www.msn.com/en-us/money/companies/harvard-bioscience-reaffirms-2026-outlook-for-2-4-revenue-growth-as-project-viking-targets-4m-annual-savings/ar-AA230kTP", "source_name": "MSN", "published_at": "2026-05-13T04:09:19", "published_display": "13 May 2026 04:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[10-Q] HARVARD BIOSCIENCE INC Quarterly Earnings Report", "summary": "Harvard Bioscience (NASDAQ: HBIO) reported Q1 2026 revenue of $20.8 million, a 4.7% decrease year-over-year, mainly due to softened demand in academic and Asia-Pacific markets. Despite a narrower net loss of $3.4 million compared to the prior year's $50.3 million loss, the compan", "url": "https://www.stocktitan.net/sec-filings/HBIO/10-q-harvard-bioscience-inc-quarterly-earnings-report-a8acb839aaed.html", "source_name": "Stock Titan", "published_at": "2026-05-12T20:40:23", "published_display": "12 May 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience Inc (HBIO) Q1 2026 Earnings Call Highlights: Revenue Growth Driven by New ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/harvard-bioscience-inc-hbio-q1-190129372.html", "source_name": "GuruFocus.com", "published_at": "2026-05-12T19:01:29+00:00", "published_display": "12 May 2026 19:01", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience Inc (HBIO) Q1 2026 Earnings Call Highlights: Revenue Growth Driven by New Product Innovations", "summary": "Harvard Bioscience Inc (HBIO) reported Q1 2026 revenue of $20.8 million, showing improved adjusted gross margin and growth driven by new product innovations such as MESH MEA, BTX, and SOHO telemetry products. Despite a slight revenue dip compared to Q1 2025 due to lower academic ", "url": "https://www.gurufocus.com/news/8851938/harvard-bioscience-inc-hbio-q1-2026-earnings-call-highlights-revenue-growth-driven-by-new-product-innovations?utm_source=yahoo_finance&utm_medium=syndication&utm_campaign=headlines&r=caf6fe0e0db70d936033da5461e60141", "source_name": "GuruFocus", "published_at": "2026-05-12T19:40:23", "published_display": "12 May 2026 19:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/ebae75ae-2862-3c7c-bfa6-bd11d4117948/harvard-bioscience%2C-inc.-q1.html", "source_name": "Moby", "published_at": "2026-05-12T17:08:24+00:00", "published_display": "12 May 2026 17:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience narrows quarterly loss as margins rise", "summary": "Harvard Bioscience (HBIO) reported its Q1 2026 financial results, showing a narrowed net loss of $3.4 million compared to $50.3 million in Q1 2025, primarily due to a significant goodwill impairment in the prior year. While revenue dipped slightly to $20.8 million, the company sa", "url": "https://www.stocktitan.net/news/HBIO/harvard-bioscience-announces-first-quarter-2026-financial-604nsc3km1xs.html", "source_name": "Stock Titan", "published_at": "2026-05-12T16:10:39", "published_display": "12 May 2026 16:10", "sentiment": "negative", "sentiment_pct": 26, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HARVARD BIOSCIENCE ($HBIO) Releases Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNbkUzeTFGT2lvVUc3MS1ZeFp0enhPamw3RUZPbXp2RGNJQTU1cGRVdWkyZ2dCVEIwcjE1NWNMZFdoekxNUDdBZlNTdjVuMmlTa0w5NVNxeW9GNmpDTUF0V2tjd04yeExGajF1RnVQSTJqSzhkaHFQc3U4VHdZNzBOcEs4U3MwcVJaclljNDkyNFZmRHphb3c?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience to Participate in Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/harvard-bioscience-participate-upcoming-investor-113000313.html", "source_name": "GlobeNewswire", "published_at": "2026-05-07T11:30:00+00:00", "published_display": "07 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "When Should You Buy Harvard Bioscience, Inc. (NASDAQ:HBIO)?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/harvard-bioscience-schedules-first-quarter-113000663.html", "source_name": "GlobeNewswire", "published_at": "2026-04-28T11:30:00+00:00", "published_display": "28 Apr 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience Announces Reverse Stock Split", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNZ1d3aHN4OWZ5UEVCUDNvQmNUY3FISVZ6Vk9rekdZQ0dNZm9Vc0FkUlN6RFdieXJiWVZ0ZjY1dmZnejFIWUk0MlV6WFNUZkY3T2Z2WFNRV3ROT1pPaVdXSnNCZmJ5cXBfQnctTXBYZEhFaE94UGc5US1kYlktYldidHM0ME5WMGVoRFhtOXdDQ0R4RlE5MXlTR0s3eGlaT0NjR1NtdnJpbXJNN3l5eHlxWnQzWG84ak15Uld1WU5VMzZzQQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-06T08:00:00+00:00", "published_display": "06 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Further Upside For Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Could Introduce Price Risks After 27% Bounce", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-04T08:00:00+00:00", "published_display": "04 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience Announces Third Quarter 2025 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOYnVHYkRCYXpjOThJNk9OQkJSMlBfWlY1NE5QRXVmaHVza0l3RlZ5cHpNekVnallPSUp1cld6Y3VmM2NpVENMcUNab19zZXpyVy1PdHo4d2VSRmZ0cGthNHg4ek0wV2tXV19VbnBmVDE2TC1GX25JUEkwMk14SXBycldCYjlyQktraUFadndoQ0tXS0FkT3FlWXZNQXJqZnIxMFNiZ0ZJN213Y2NPYV9mcWNNQlF6NjdLVUloZnBPVS1zWUh4eWJ2WEFmNWp0QlRWNlZmSXR4Yk4?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-11-06T08:00:00+00:00", "published_display": "06 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience inks U.S. distribution agreement with Fisher Scientific", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPc0xncF9nYTZaZWR6aFdYWXc1Y3VlX2lIZFZWS25QSjlBTWFyNVFZcE5NSXhETXo1eWt4eUd0U1V2T1paYTlLMHZvd2xvYXp4dkFSTVBabXNxOGlveXdSd2g2aGlZTk1vV3BhQUNBNDRIZE4xSkoyOGxoTkdkLUR6V0tscGlIbWFmWnpVWERGRXF2dDlZRkM4RVhTVGNDQU1pVmJjWmVn?oc=5", "source_name": "Worcester Business Journal", "published_at": "2025-09-16T07:00:00+00:00", "published_display": "16 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience, Inc. (NASDAQ:HBIO) Just Reported, And Analysts Assigned A US$3.00 Price Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOQmtJbGpsSU5QZkpxam15UEh1WThicmdtLVdrNE1VYkdKYVlhN2VQaUo4RjAwYWJNSXhOY2lqTnZpalduRWdRZzctXzFzZ1dMVXFBb0RzdTJTU1Q5aGVvUTlTLXdKUHV6MmRMVFZuaDhHWjh0OE1fZGs3SVFfYjNDQ2NldWlRbUw5RlEyYnhFS3BFUGRadjQ4bGxSQmtaMFY1XzZmQVVHQ043aU1jMFc2cTE2aFhYaHhCQk9DZ1puTUd3ZXN6N2h0NjRkMDNVTkZieWtOcmZzQUlqLVBEeGF0bjhSbXpvZ1nSAewBQVVfeXFMTXlGbV80c3k3TEMyWENfX21jZWhuQUJaaEpDcjhLX1VOWVlXalpxZVlNb0xpTWJpcVNPMXlVTnc4RFI1OVBQS2VfNFZrSFpBakdJWWwzR0VWTWNUV3N4YVNMM3RuMkZsY0Z6WHJIdEhsQXp4NGZGN2xkdkhsRUNxUVlHSUl3Q05yaTdEc2JLc2JYaVA3dUFNRUdlQXNqTTBab3VOeEFNZWxGSDJNTkR0bk9EUTFpemcxX1ZXeE5iQUFmY1FwdWdlRl9KOUItR2h5cDNqQ3NacU1wSWVmNW45NExQRjNVbFYySW9nQ20?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-14T07:00:00+00:00", "published_display": "14 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience replaces retiring CEO, attempts to regain Nasdaq compliance", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPeTEwR3I1VXBGOTJRdFdjeUZ6UzJpbUZjUWR0eTFheXhoTlhIbk5sUlRwaGxtWF9icTVNODFIQy14WVprQlJqbzFrdi02bW1pcGtraFJySWdfMzA3eWdDTlZXNmpVV051QUVuVHpuajF5TmlUdFdpQ1Q3Q0ZTRFk2aENMWC1TdUw1T3h5emwtNWdmd3Fqd3ZFNGM2TERiN3lmVEJSVjdXSTFEdmc0?oc=5", "source_name": "Worcester Business Journal", "published_at": "2025-07-17T07:00:00+00:00", "published_display": "17 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Biosci (HBIO) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE44M2U1TXNnMGN2RlBDaGN3Z3hzWVdIdzl4MnNqVUE0NXdQWk1IZTlieXN5ejA3Q2NjYUNhNEg0V3QyTW5jdU8wV3lhdXBrVzR2ZWVF?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T17:25:33+00:00", "published_display": "24 Apr 2025 17:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience (HBIO) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE9ZeVpWQmwwRnJSMGNIUjUwNmFhZ0Mwd1VBVEsxZXFpZnM4bVoyZzBlMkVTY3NZZHdMZ25jRE1RaUFVeG5RMGtDZm1JekVJSHBsUVY2MUZjeU9ybjV5NFFMeEtiNThrdw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T19:51:32+00:00", "published_display": "11 May 2024 19:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Type Of Shareholders Make Up Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Share Registry?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxNdUpuMk5maFlKVGRzamFubHlOc0NYT0FtUU5RSEpQb0lkUUt5MVAyT3NPaTdsa1hEZVR3cmVvRS1MbExfQnlOaG9PSFhWaFMzV0FlWVZCYWN2SE1XY3dCZmpjWGdXalAxU1dXMVJIMHpTX1hHbG1WSEljTnVjdHp4a29kVEx0UlBtTWp3eldJTQ?oc=5", "source_name": "Market source", "published_at": "2022-07-28T07:00:00+00:00", "published_display": "28 Jul 2022 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HBIO Stock Price and Chart \u2014 NASDAQ:HBIO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1GZlcxZE9IcS02MWE1LWlwZ1dlOTJLM2lJX1NMTXd1TnNWYnBFM2VkdmFqM3dSZWtYS1ZtRTB3bkh5cVhvX0VQeHd2QkZfTHFRcUt4d1NGdXYwek5C?oc=5", "source_name": "TradingView", "published_at": "2017-07-21T03:14:26+00:00", "published_display": "21 Jul 2017 03:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Harvard Bioscience focuses on life science instruments as investors weigh long-term demand", "summary": "Harvard Bioscience (HBIO) is a life science tools company that specializes in preclinical research instruments and laboratory systems. The company's business model relies on selling capital equipment, consumables, and services to pharmaceutical and biotechnology companies, contra", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/harvard-bioscience-focuses-on-life-science-instruments-as-investors-weigh/69732093", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-09T13:11:50", "published_display": "09 Jul 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience focuses on lab equipment growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPVTBhU2hyMS1IZUtsVW5vV09PSWVGdFd0OW5adnVtM2QzMDRUd0ZFUG5DemRGbjdGbDA2Qkw4TnpjdGFwc2JfZEpjMTVRa0cyVjVMRllMMWNHYTA4ZkpNZWRBTnBtUElaZlVCQWJEYnFmbW12ZVF5T3JwcXlBZC13TXR1aFVXc3ItMDVINUVMZkNLSmlkaFpuaEtwXzR3bGs0eGl0RHpodm4wcHBDMUE?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-07T20:22:01+00:00", "published_display": "07 Jul 2026 20:22", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience (HBIO) Hovers Near Support Amid Low-Volume Trading - Bollinger Walk", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQT1ZtRTRxLW10V1pnMVAxRC1EaDIzOTFKMUxOelZoU2R0NjlZMnAyX1c5ZHNER2tuWnBCWkdfZ2tLbWlrbkhHaTE4eG51OXBOT2hwNk1mRWtUa1hWM1IxU1dCMkFQa2JYbTVzWGRDTWZhNjBrT25VV2dNUkZhdHE2VEJYWThGcWNDbFQ1TTlkaVJ4WDFXNlFvX25GTGtNbGlTMVR6WVBCU3dWZkJmRWww?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience | SD: Specialized disclosure report", "summary": "This article is a specialized disclosure report from Harvard Bioscience. The content of the report is provided in the document.", "url": "https://www.moomoo.com/news/notice/307395749/harvard-bioscience-sd-specialized-disclosure-report", "source_name": "Moomoo", "published_at": "2026-07-04T15:10:59", "published_display": "04 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience, Inc. Actuals & Estimates (NASDAQ:HBIO)", "summary": "This article provides an overview of Harvard Bioscience, Inc. (HBIO) stock performance, analyst estimates, and financial data. It covers current stock price, market capitalization, earnings, revenue, and future forecasts. The company's next earnings report is expected on July 30,", "url": "https://www.tradingview.com/symbols/NASDAQ-HBIO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:40:10", "published_display": "26 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Harvard Bioscience, Inc. \u2013 NASDAQ:HBIO", "summary": "This article provides a brief snapshot of Harvard Bioscience, Inc. (NASDAQ: HBIO) financial data, specifically focusing on its forward price-to-sales ratio. It appears to be a stub or an outdated page from a financial data platform like TradingView, intended to display financial ", "url": "https://www.tradingview.com/symbols/NASDAQ-HBIO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T13:12:05", "published_display": "25 Jun 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HBIO Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Harvard Bioscience, Inc. (HBIO) stock, based on analyst opinions. It details current stock performance, historical highs and lows, volatility, market capitalization, and upcoming earnings reports, along with financial data lik", "url": "https://www.tradingview.com/symbols/NASDAQ-HBIO/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-23T17:41:15", "published_display": "23 Jun 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience Inc (HBIO) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Harvard Bioscience Inc (HBIO) has a current financial score of 7.02, indicating a weak financial status despite high operating efficiency, ranking 114 out of 203 in its industry. The company's recent quarterly revenue decreased by 4.68% year-over-year to $20.75M, while net profit", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hbio/financial-health", "source_name": "TradingKey", "published_at": "2026-06-23T08:13:38", "published_display": "23 Jun 2026 08:13", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience (HBIO) Slips Slightly, Holding Above Support at $5.71 - Quality Factor", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOWE96ZG1adjg0bHE5dm1zb2JpWjM1T2puRUJsU1pxMGF4bEJfMTExVS1Uc3JrQjd6NXlDVFNKRHBjRTBLODdaLVZXWThVYXVqeUZDQjRJTkNsek5hakdnUENuVWZWaFMxZXh3cmZPTW5EZnRhR3hGdW9rRy1Bb0tSZ2xsNmFzVEtFRlpOTU9Ba045Y3Nfempya1dXQXRHYk8zbV8xVmRmOXRyb3VsTXc?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience holds key trading range, shares between support and resistance", "summary": "Harvard Bioscience (HBIO) is currently trading within a defined range on Nasdaq, with technical analysis indicating support at $5.10 and resistance at $6.65. Despite a relatively solid momentum score, short-term signals are cautious, with more sell than buy indicators reported by", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/harvard-bioscience-holds-key-trading-range-shares-between-support-and/69606091", "source_name": "AD HOC NEWS", "published_at": "2026-06-22T20:10:18", "published_display": "22 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience Inc (HBIO) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Harvard Bioscience Inc (HBIO), noting its current valuation score is 9.02, ranking it 46 out of 203 in the Healthcare Equipment & Supplies industry. It highlights the company's P/E ratio of -2.77, while stating that relevant data for ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hbio/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T20:10:31", "published_display": "18 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience Inc (HBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Harvard Bioscience Inc (HBIO), detailing its current price momentum score, support and resistance levels, and indicator readings. It also outlines the stock's moving average status, with a current overall signal of \"Sell\" based on tec", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hbio/technical", "source_name": "TradingKey", "published_at": "2026-06-18T10:38:54", "published_display": "18 Jun 2026 10:38", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience Inc (HBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Harvard Bioscience Inc (HBIO), highlighting its current earnings forecast score and analyst ratings. It details the average price target, expected revenue for the next quarter, and historical as well as forecasted EPS. The report ind", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hbio/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T09:38:54", "published_display": "18 Jun 2026 09:38", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience Inc (HBIO) Institutional Confidence", "summary": "Harvard Bioscience Inc (HBIO) has an institutional shareholding score of 5.00, placing it 109th out of 204 in the Healthcare Equipment & Supplies industry. Institutional shareholding proportion increased by 13.62% quarter-over-quarter to 54.17%. James Simons is the largest instit", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hbio/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T09:38:54", "published_display": "18 Jun 2026 09:38", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Harvard Bioscience (HBIO) granted 16,556 restricted stock units", "summary": "Harvard Bioscience director Katherine A. Eade was granted 16,556 restricted stock units (RSUs) of common stock at no cost. These RSUs will vest either before the company's next annual meeting or one year from the grant date, whichever comes first. Following this transaction, Eade", "url": "https://www.stocktitan.net/sec-filings/HBIO/form-4-harvard-bioscience-inc-insider-trading-activity-7ad08f78d51f.html", "source_name": "Stock Titan", "published_at": "2026-06-12T16:08:44", "published_display": "12 Jun 2026 16:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience (HBIO) director awarded 16,556 restricted stock units", "summary": "Harvard Bioscience director William Snider was granted 16,556 restricted stock units (RSUs) as compensation, which will vest either before the next annual meeting or one year from the grant date. This award increases his total holdings to 48,556 common share equivalents, includin", "url": "https://www.stocktitan.net/sec-filings/HBIO/form-4-harvard-bioscience-inc-insider-trading-activity-ae3acf126e4c.html", "source_name": "Stock Titan", "published_at": "2026-06-11T16:40:05", "published_display": "11 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience (NASDAQ: HBIO) awards director 16,556 RSUs", "summary": "Harvard Bioscience (NASDAQ: HBIO) director Stephen J. Denelsky was granted 16,556 restricted stock units (RSUs) as reported in a Form 4 SEC filing. These RSUs will vest either immediately before the company's next annual meeting or one year from the grant date, serving as a time-", "url": "https://www.stocktitan.net/sec-filings/HBIO/form-4-harvard-bioscience-inc-insider-trading-activity-9a5a18d8c248.html", "source_name": "Stock Titan", "published_at": "2026-06-11T13:39:17", "published_display": "11 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Harvard Bioscience (HBIO) awarded 16,556 RSUs", "summary": "Harvard Bioscience director Seth Benjamin Benson was granted 16,556 restricted stock units (RSUs) of common stock at a price of $0.0000 per share. These RSUs will vest either immediately before the company\u2019s next annual meeting or one year from the grant date, whichever comes fir", "url": "https://www.stocktitan.net/sec-filings/HBIO/form-4-harvard-bioscience-inc-insider-trading-activity-be1b781c385b.html", "source_name": "Stock Titan", "published_at": "2026-06-11T13:39:17", "published_display": "11 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience | 8-K: Harvard Bioscience Announces First Quarter 2026 Financial Results", "summary": "This article is a placeholder indicating that Harvard Bioscience announced its First Quarter 2026 Financial Results via an 8-K filing. The content displayed is merely a document placeholder, suggesting the detailed results would be within the actual 8-K filing.", "url": "https://www.moomoo.com/news/notice/307279199/harvard-bioscience-8-k-harvard-bioscience-announces-first-quarter-2026", "source_name": "Moomoo", "published_at": "2026-06-03T03:10:21", "published_display": "03 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience (NASDAQ: HBIO) shareholders approve equity and ESPP share increases", "summary": "Harvard Bioscience, Inc. shareholders approved key proposals at their 2026 Annual Meeting, including an increase of 400,000 shares for their 2021 Incentive Plan and amendments to the Employee Stock Purchase Plan. Shareholders also re-elected two Class II directors, ratified Grant", "url": "https://www.stocktitan.net/sec-filings/HBIO/8-k-harvard-bioscience-inc-reports-material-event-4d7925889f27.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:09:46", "published_display": "02 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience (HBIO) price target increased by 200.00% to 6.12", "summary": "This article reports that the price target for Harvard Bioscience (HBIO) has been significantly increased by 200.00% to $6.12. No further details are provided in the snippet.", "url": "https://www.msn.com/en-us/money/topstocks/harvard-bioscience-hbio-price-target-increased-by-20000-to-612/ar-AA1ZAgZk", "source_name": "MSN", "published_at": "2026-06-01T01:39:44", "published_display": "01 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HBIO - Harvard Bioscience Inc Website Traffic and Mobile Apps Usage", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE5DZjRUNHZJMVBFTVlfOENRQkNKYko1bWRtSVozUmhDeUl0cFBfSUdZXzRuX1AxUmNBUldiSVpCeWVaOTZpNDJDOUEwMGJ4UQ?oc=5", "source_name": "Finviz", "published_at": "2026-05-27T17:43:19+00:00", "published_display": "27 May 2026 17:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HBIO PE Ratio & Valuation, Is HBIO Overvalued", "summary": "Harvard Bioscience Inc (HBIO) is currently considered to be in the \"Fair zone,\" with its forward PE ratio of 15.06 fairly comparable to its five-year average of 23.52. The fair price for HBIO is estimated to be between $2.40 and $14.02 based on a relative valuation method. While ", "url": "https://intellectia.ai/en/stock/HBIO/valuation", "source_name": "Intellectia AI", "published_at": "2026-05-25T00:40:21", "published_display": "25 May 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience stock (US4169061052): Q2 2025 mixed results still define the story", "summary": "Harvard Bioscience (HBIO) reported mixed results for Q2 2025, with revenue missing estimates but adjusted earnings matching expectations thanks to improved cash flow and cost control. The company, a small-cap medtech supplier, operates in the life sciences research sector, making", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/harvard-bioscience-stock-us4169061052-q2-2025-mixed-results-still/69390990", "source_name": "AD HOC NEWS", "published_at": "2026-05-21T12:10:11", "published_display": "21 May 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:HBIO) 2026-05-15", "summary": "Harvard Bioscience, Inc. (NASDAQ:HBIO) published its Q1 2026 earnings call presentation, reporting an EPS of -$0.33, missing estimates by $0.30, and revenue of $20.76M, a 4.68% year-over-year decrease, missing by $445.00K. The article highlights that the slide deck was released i", "url": "https://seekingalpha.com/article/4905504-harvard-bioscience-inc-2026-q1-results-earnings-call-presentation?source=feed_all_articles", "source_name": "Seeking Alpha", "published_at": "2026-05-16T00:09:11", "published_display": "16 May 2026 00:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience (HBIO) insider entity reports 293,676 shares, 6.5% stake", "summary": "Harvard Bioscience (HBIO) investor Adam M. Hutt, as Managing Member of Leviticus Partners, has filed a Schedule 13G/A, disclosing beneficial ownership of 293,676 shares of Common Stock, representing a 6.5% stake in the company. The filing indicates sole voting and dispositive pow", "url": "https://www.stocktitan.net/sec-filings/HBIO/schedule-13g-a-harvard-bioscience-inc-amended-passive-investment-disc-d8fcc6606613.html", "source_name": "Stock Titan", "published_at": "2026-05-14T16:39:10", "published_display": "14 May 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discontinued operations of Harvard Bioscience, Inc. \u2013 FWB:HBI0", "summary": "The article reports on the discontinued operations of Harvard Bioscience, Inc., traded on the Frankfurt Stock Exchange under the symbol HBI0. It appears to be a financial news brief, likely indicating a change in the company's operational status. The content is brief and serves a", "url": "https://www.tradingview.com/symbols/FWB-HBI0/financials-income-statement/discontinued-operations/", "source_name": "TradingView", "published_at": "2026-05-13T23:40:23", "published_display": "13 May 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience, Inc. (NASDAQ:HBIO) Q1 2026 Earnings Call Transcript", "summary": "Harvard Bioscience, Inc. (NASDAQ:HBIO) reported its Q1 2026 earnings, highlighting continued progress in transforming into a translational science market supplier. The company beat earnings expectations with an EPS of $-0.33, against an expected $-0.62, and saw revenue of $20.8 m", "url": "https://www.insidermonkey.com/blog/harvard-bioscience-inc-nasdaqhbio-q1-2026-earnings-call-transcript-1761091/", "source_name": "Insider Monkey", "published_at": "2026-05-13T12:08:50", "published_display": "13 May 2026 12:08", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience: Q1 Earnings Snapshot", "summary": "Harvard Bioscience Inc. (HBIO) reported a Q1 loss of $3.4 million, or 77 cents per share. Adjusted for certain costs, the loss was 33 cents per share. The medical instruments company also projected Q2 revenue to be between $20.5 million and $22.5 million.", "url": "https://www.ktvb.com/article/syndication/associatedpress/harvard-bioscience-q1-earnings-snapshot/616-7a6b632f-bd2c-4309-8b66-26b56347923e", "source_name": "KTVB", "published_at": "2026-05-13T05:09:11", "published_display": "13 May 2026 05:09", "sentiment": "negative", "sentiment_pct": 36, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience Announces First Quarter 2026 Financial Results", "summary": "Harvard Bioscience (Nasdaq: HBIO) reported its first-quarter 2026 financial results, with revenues of $20.8 million and a gross margin of 59%. The company is progressing with the consolidation of manufacturing operations and reaffirmed its full-year 2026 financial guidance, antic", "url": "https://www.sahmcapital.com/news/content/harvard-bioscience-announces-first-quarter-2026-financial-results-2026-05-12", "source_name": "Sahm", "published_at": "2026-05-13T04:39:10", "published_display": "13 May 2026 04:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience reaffirms 2026 outlook for 2%-4% revenue growth as Project Viking targets $4M annual savings", "summary": "Harvard Bioscience (HBIO) has reaffirmed its 2026 outlook, projecting 2-4% organic revenue growth and an adjusted EBITDA margin of 20-22%. The company's 'Project Viking' initiative is expected to achieve approximately $4 million in annual run-rate savings, contributing to its goa", "url": "https://www.msn.com/en-us/money/companies/harvard-bioscience-reaffirms-2026-outlook-for-2-4-revenue-growth-as-project-viking-targets-4m-annual-savings/ar-AA230kTP", "source_name": "MSN", "published_at": "2026-05-13T04:09:19", "published_display": "13 May 2026 04:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[10-Q] HARVARD BIOSCIENCE INC Quarterly Earnings Report", "summary": "Harvard Bioscience (NASDAQ: HBIO) reported Q1 2026 revenue of $20.8 million, a 4.7% decrease year-over-year, mainly due to softened demand in academic and Asia-Pacific markets. Despite a narrower net loss of $3.4 million compared to the prior year's $50.3 million loss, the compan", "url": "https://www.stocktitan.net/sec-filings/HBIO/10-q-harvard-bioscience-inc-quarterly-earnings-report-a8acb839aaed.html", "source_name": "Stock Titan", "published_at": "2026-05-12T20:40:23", "published_display": "12 May 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience Inc (HBIO) Q1 2026 Earnings Call Highlights: Revenue Growth Driven by New ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/harvard-bioscience-inc-hbio-q1-190129372.html", "source_name": "GuruFocus.com", "published_at": "2026-05-12T19:01:29+00:00", "published_display": "12 May 2026 19:01", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience Inc (HBIO) Q1 2026 Earnings Call Highlights: Revenue Growth Driven by New Product Innovations", "summary": "Harvard Bioscience Inc (HBIO) reported Q1 2026 revenue of $20.8 million, showing improved adjusted gross margin and growth driven by new product innovations such as MESH MEA, BTX, and SOHO telemetry products. Despite a slight revenue dip compared to Q1 2025 due to lower academic ", "url": "https://www.gurufocus.com/news/8851938/harvard-bioscience-inc-hbio-q1-2026-earnings-call-highlights-revenue-growth-driven-by-new-product-innovations?utm_source=yahoo_finance&utm_medium=syndication&utm_campaign=headlines&r=caf6fe0e0db70d936033da5461e60141", "source_name": "GuruFocus", "published_at": "2026-05-12T19:40:23", "published_display": "12 May 2026 19:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/ebae75ae-2862-3c7c-bfa6-bd11d4117948/harvard-bioscience%2C-inc.-q1.html", "source_name": "Moby", "published_at": "2026-05-12T17:08:24+00:00", "published_display": "12 May 2026 17:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience narrows quarterly loss as margins rise", "summary": "Harvard Bioscience (HBIO) reported its Q1 2026 financial results, showing a narrowed net loss of $3.4 million compared to $50.3 million in Q1 2025, primarily due to a significant goodwill impairment in the prior year. While revenue dipped slightly to $20.8 million, the company sa", "url": "https://www.stocktitan.net/news/HBIO/harvard-bioscience-announces-first-quarter-2026-financial-604nsc3km1xs.html", "source_name": "Stock Titan", "published_at": "2026-05-12T16:10:39", "published_display": "12 May 2026 16:10", "sentiment": "negative", "sentiment_pct": 26, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HARVARD BIOSCIENCE ($HBIO) Releases Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNbkUzeTFGT2lvVUc3MS1ZeFp0enhPamw3RUZPbXp2RGNJQTU1cGRVdWkyZ2dCVEIwcjE1NWNMZFdoekxNUDdBZlNTdjVuMmlTa0w5NVNxeW9GNmpDTUF0V2tjd04yeExGajF1RnVQSTJqSzhkaHFQc3U4VHdZNzBOcEs4U3MwcVJaclljNDkyNFZmRHphb3c?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience to Participate in Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/harvard-bioscience-participate-upcoming-investor-113000313.html", "source_name": "GlobeNewswire", "published_at": "2026-05-07T11:30:00+00:00", "published_display": "07 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "When Should You Buy Harvard Bioscience, Inc. (NASDAQ:HBIO)?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/harvard-bioscience-schedules-first-quarter-113000663.html", "source_name": "GlobeNewswire", "published_at": "2026-04-28T11:30:00+00:00", "published_display": "28 Apr 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience Announces Reverse Stock Split", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNZ1d3aHN4OWZ5UEVCUDNvQmNUY3FISVZ6Vk9rekdZQ0dNZm9Vc0FkUlN6RFdieXJiWVZ0ZjY1dmZnejFIWUk0MlV6WFNUZkY3T2Z2WFNRV3ROT1pPaVdXSnNCZmJ5cXBfQnctTXBYZEhFaE94UGc5US1kYlktYldidHM0ME5WMGVoRFhtOXdDQ0R4RlE5MXlTR0s3eGlaT0NjR1NtdnJpbXJNN3l5eHlxWnQzWG84ak15Uld1WU5VMzZzQQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-06T08:00:00+00:00", "published_display": "06 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Further Upside For Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Could Introduce Price Risks After 27% Bounce", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-04T08:00:00+00:00", "published_display": "04 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience Announces Third Quarter 2025 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOYnVHYkRCYXpjOThJNk9OQkJSMlBfWlY1NE5QRXVmaHVza0l3RlZ5cHpNekVnallPSUp1cld6Y3VmM2NpVENMcUNab19zZXpyVy1PdHo4d2VSRmZ0cGthNHg4ek0wV2tXV19VbnBmVDE2TC1GX25JUEkwMk14SXBycldCYjlyQktraUFadndoQ0tXS0FkT3FlWXZNQXJqZnIxMFNiZ0ZJN213Y2NPYV9mcWNNQlF6NjdLVUloZnBPVS1zWUh4eWJ2WEFmNWp0QlRWNlZmSXR4Yk4?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-11-06T08:00:00+00:00", "published_display": "06 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience inks U.S. distribution agreement with Fisher Scientific", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPc0xncF9nYTZaZWR6aFdYWXc1Y3VlX2lIZFZWS25QSjlBTWFyNVFZcE5NSXhETXo1eWt4eUd0U1V2T1paYTlLMHZvd2xvYXp4dkFSTVBabXNxOGlveXdSd2g2aGlZTk1vV3BhQUNBNDRIZE4xSkoyOGxoTkdkLUR6V0tscGlIbWFmWnpVWERGRXF2dDlZRkM4RVhTVGNDQU1pVmJjWmVn?oc=5", "source_name": "Worcester Business Journal", "published_at": "2025-09-16T07:00:00+00:00", "published_display": "16 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience, Inc. (NASDAQ:HBIO) Just Reported, And Analysts Assigned A US$3.00 Price Target", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-14T07:00:00+00:00", "published_display": "14 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience replaces retiring CEO, attempts to regain Nasdaq compliance", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPeTEwR3I1VXBGOTJRdFdjeUZ6UzJpbUZjUWR0eTFheXhoTlhIbk5sUlRwaGxtWF9icTVNODFIQy14WVprQlJqbzFrdi02bW1pcGtraFJySWdfMzA3eWdDTlZXNmpVV051QUVuVHpuajF5TmlUdFdpQ1Q3Q0ZTRFk2aENMWC1TdUw1T3h5emwtNWdmd3Fqd3ZFNGM2TERiN3lmVEJSVjdXSTFEdmc0?oc=5", "source_name": "Worcester Business Journal", "published_at": "2025-07-17T07:00:00+00:00", "published_display": "17 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Biosci (HBIO) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE44M2U1TXNnMGN2RlBDaGN3Z3hzWVdIdzl4MnNqVUE0NXdQWk1IZTlieXN5ejA3Q2NjYUNhNEg0V3QyTW5jdU8wV3lhdXBrVzR2ZWVF?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T17:25:33+00:00", "published_display": "24 Apr 2025 17:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harvard Bioscience (HBIO) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE9ZeVpWQmwwRnJSMGNIUjUwNmFhZ0Mwd1VBVEsxZXFpZnM4bVoyZzBlMkVTY3NZZHdMZ25jRE1RaUFVeG5RMGtDZm1JekVJSHBsUVY2MUZjeU9ybjV5NFFMeEtiNThrdw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T19:51:32+00:00", "published_display": "11 May 2024 19:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Type Of Shareholders Make Up Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Share Registry?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxNdUpuMk5maFlKVGRzamFubHlOc0NYT0FtUU5RSEpQb0lkUUt5MVAyT3NPaTdsa1hEZVR3cmVvRS1MbExfQnlOaG9PSFhWaFMzV0FlWVZCYWN2SE1XY3dCZmpjWGdXalAxU1dXMVJIMHpTX1hHbG1WSEljTnVjdHp4a29kVEx0UlBtTWp3eldJTQ?oc=5", "source_name": "Market source", "published_at": "2022-07-28T07:00:00+00:00", "published_display": "28 Jul 2022 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HBIO Stock Price and Chart \u2014 NASDAQ:HBIO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1GZlcxZE9IcS02MWE1LWlwZ1dlOTJLM2lJX1NMTXd1TnNWYnBFM2VkdmFqM3dSZWtYS1ZtRTB3bkh5cVhvX0VQeHd2QkZfTHFRcUt4d1NGdXYwek5C?oc=5", "source_name": "TradingView", "published_at": "2017-07-21T03:14:26+00:00", "published_display": "21 Jul 2017 03:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 90, "total_relevant": 50, "sentiment_summary": {"positive": 11, "negative": 5, "neutral": 34, "score": 51, "total": 50, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 13.75, "count": 25}, {"event": "earnings", "label": "Earnings", "weight": 10.25, "count": 18}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 11, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 6.14, "latest_week": "2026-07-10", "one_week_move": -0.2, "four_week_move": 1.0, "twelve_week_move": 0.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.384373, "market_dynamics_buy_signal": false, "relative_strength": -5.948201, "fair_value_gap": -71.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 46.1695, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.2% over one week, +1.0% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 48, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 9}, {"label": "TradingView", "count": 5}, {"label": "TradingKey", "count": 5}, {"label": "GlobeNewswire", "count": 4}, {"label": "simplywall.st", "count": 3}, {"label": "dars.gov.et", "count": 2}, {"label": "Moomoo", "count": 2}, {"label": "AD HOC NEWS", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 50}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 25}, {"label": "Earnings", "count": 18}, {"label": "Analyst action", "count": 3}, {"label": "Macro sensitivity", "count": 1}, {"label": "Regulatory and legal", "count": 1}, {"label": "Deals and strategy", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "50", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.2% over one week, +1.0% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Harvard Bioscience focuses on life science instruments as investors weigh long-term demand"}], "updated_at": "2026-07-17T16:21:53.612788+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}